Spat over IMI funding and intellectual property

. 2011 Jun 7;29(6):473.

doi: 10.1038/nbt0611-473a.

Gunjan Sinha. Nat Biotechnol. 2011.

. 2011 Jun 7;29(6):473.

doi: 10.1038/nbt0611-473a.

No abstract available

Comment in

IMI moves forward.
Strohmeier R, Draghia-Akli R, Rys A, Silvan PO, Lennon T, Incerti C, Bergström R, Chibout S, Doliveux R, Andersen PH. Strohmeier R, et al. Nat Biotechnol. 2011 Aug 5;29(8):689-90; reply 690. doi: 10.1038/nbt.1944. Nat Biotechnol. 2011. PMID: 21822236 No abstract available.

IMI moves forward.
Strohmeier R, Draghia-Akli R, Rys A, Silvan PO, Lennon T, Incerti C, Bergström R, Chibout S, Doliveux R, Andersen PH. Strohmeier R, et al. Nat Biotechnol. 2011 Aug 5;29(8):689-90; reply 690. doi: 10.1038/nbt.1944. Nat Biotechnol. 2011. PMID: 21822236 No abstract available.
Mayo clinic office of intellectual property-exploring and encouraging invention and innovation through unique mayo clinic funding opportunities.
Anderson K. Anderson K. J Cardiovasc Transl Res. 2008 Dec;1(4):278-80. doi: 10.1007/s12265-008-9058-5. Epub 2008 Sep 26. J Cardiovasc Transl Res. 2008. PMID: 20559935 No abstract available.
In vogue with venture.
Patou G. Patou G. Nat Biotechnol. 2011 Nov;29(11):967-9. Nat Biotechnol. 2011. PMID: 22175076 No abstract available.
[From drug cost to drug price: steps and decisional processes].
Bruyninckx M, Nourissier C. Bruyninckx M, et al. Presse Med. 2012 May;41 Suppl 1:S40-3. doi: 10.1016/j.lpm.2012.02.016. Epub 2012 Apr 8. Presse Med. 2012. PMID: 22487715 French. No abstract available.
Can open-source drug R&D repower pharmaceutical innovation?
Munos B. Munos B. Clin Pharmacol Ther. 2010 May;87(5):534-6. doi: 10.1038/clpt.2010.26. Clin Pharmacol Ther. 2010. PMID: 20407458 Review.

IMI moves forward.
Strohmeier R, Draghia-Akli R, Rys A, Silvan PO, Lennon T, Incerti C, Bergström R, Chibout S, Doliveux R, Andersen PH. Strohmeier R, et al. Nat Biotechnol. 2011 Aug 5;29(8):689-90; reply 690. doi: 10.1038/nbt.1944. Nat Biotechnol. 2011. PMID: 21822236 No abstract available.